News

ELF use of the “hot” technique MST

The European Lead Factory (ELF) scientists are not shy of applying new techniques to deliver the best possible results. A recent perspective, published in SLAS Discovery, describes how getting hot (or not) can help in the triaging of primary HTS hits.

PhD thesis enhanced with ELF collaboration and compounds

On 30 January 2018, Stefan Baumeister defended his dissertation ‘Investigation of the properties of Acyl Protein Thioesterases and their role in Ras depalmitoylation’ at the Max Planck Institute of Molecular Physiology (MPI) in Dortmund. His thesis describes structural determinants for selectivity between two closely related enzymes. Specific inhibitors could be optimized thanks to compounds derived from Dr. Sonja Siever’s ELF programme. The new insights can prove important for understanding the role of these enzymes in the course of cancer.

SciLifeLab signs Memorandum of Understanding

The SciLifeLab Director and the European Lead Factory executives of the European Screening Centre and the Public Chemistry Consortium have signed a Memorandum of Understanding for collaboration in future initiatives.

European Lead Factory one of IMI’s most high-profile projects

Until now, the Innovative Medicines Initiative (IMI) has launched almost 100 projects to tackle the barriers that currently limit the efficiency, effectiveness and quality of medical research and drug development.

Spin-out Keapstone Therapeutics receives further funding

Based on the hits generated by the European Lead Factory, Dr Richard Mead, University of Sheffield, started the spin-out virtual biotech Keapstone Therapeutics, a world-first type of partnership between Parkinson's UK and the University of Sheffield. Keapstone Therapeutics aims to develop a new therapy for motor neurone disease (MND/ALS) and/or Parkinson’s disease.

ELF Chemistry event brings together scientists in Belgium

The European Lead Factory (ELF) acknowledges the need for open exchange between researchers with different professional backgrounds and puts a focus on the career development of young scientists. Therefore, the European Lead Factory annually invites young talented EU Lead Factory chemists from participating small and medium-sized enterprises (SMEs) and academic institutions to a so-called Learnings and Achievements meeting, where they can present their scientific work, interact with colleagues and liaise with representatives from participating established pharmaceutical companies and SME partners.

Archive

Latest news

The European Lead Factory (ELF) secured a total project budget of EUR 36.5 million under the second framework of the Innovative Medicines Initiative (IMI). 20 partners in 7 countries will push forward the transformation of potential drug targets to new medicines in the new project ESCulab (...

The European Lead Factory has successfully accelerated the process of drug discovery. A recently published public summary of results so far clearly shows the benefits of collaborative drug discovery in the European arena.

Follow us at

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n' 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in kind contribution.

This project has also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806948: ‘ESCulab: European Screening Centre; Unique Library for Attractive Biology’. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Medicines for Malaria Venture (MMV).